Analog Devices, Inc. (NASDAQ:ADI) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -0.11% to $64.13. Analog Devices, Inc. (ADI) announced the acquisition of the Cyber Security Solutions (CSS) business of Sypris Electronics LLC. This acquisition represents a significant leap forward in ADI’s ability to deliver secure high-performance analog solutions demanded by current and future market needs.
The CSS business of Sypris Electronics, LLC is well-known as a leader in secure system and software products and technology. For more than 50 years, Sypris has built a proven track record of delivering high-assurance information security services to the world’s most demanding customers, including military and government organizations needing to protect against sophisticated nation-state level threats and attacks. The share price of ADI attracts active investors, as stock price of week volatility recorded 1.62%. The stock is going forward to its 52-week low with 37.87% and lagging behind from its 52-week high price with -4.15%.
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -14.01% to close at $10.07 with the total traded volume of 2.2 Million shares. OncoMed Pharmaceuticals, Inc. (OMED) announced that pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $10.00 per share. Net proceeds to OncoMed from this offering are expected to be approximately $51.4 million after underwriting discounts and commissions and estimated offering expenses.
The offering is expected to close on or about August 23, 2016, subject to customary closing conditions. The Company has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 825,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The firm has institutional ownership of 72.80%, while insider ownership included 0.30%. Its price to sales ratio ended at 12.43. OMED attains analyst recommendation of 1.90 with week performance of -14.22%.
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) [Trend Analysis] surged reacts as active mover, shares an advance 8.20% to traded at $13.98 and the percentage gap between open changing to regular change was 3.10%. Aimmune Therapeutics, Inc. (AIMT) announced that management will host a conference call to highlight the results of an independent academic clinical trial demonstrating the ability of low-dose oral immunotherapy to induce sustained unresponsiveness in peanut-allergic children under three years of age.
Management will also discuss the potential positive implications of these results for the company’s ongoing development program of AR101, its biologic oral immunotherapy for desensitization of patients with peanut allergy. AR101 is currently under investigation in the Phase 3 PALISADE trial enrolling peanut-allergic patients 4-55 years of age. The firm’s current ratio calculated as 34.80 for the most recent quarter. As far as the returns are concern, the return on equity was recorded as -32.30%, while its return on asset stayed at -27.50%.